Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 29, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [4] - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=176107&from=3 CLASS PERIOD: July 26, 2024 to Se ...

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) for violations of the federal securities laws on behalf of investors who purchased or acquired DexCom securities between July 26, 2024 and September 17, 2025, inclusive (the “Class Period”). On October 27, 2025, a complaint was filed against the Company and cert ...

Accessibility StatementSkip Navigation CONTACT: The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form-2/?id=176087&from=4 CLASS PERIOD: July 26, 2024 to September 17, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes ...

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud, alleging that the company misled investors about the reliability and accuracy of its continuous glucose monitoring systems, leading to significant stock declines [2][4]. Company Overview - DexCom, Inc. specializes in manufacturing continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7 models [5]. Allegations and Issues - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised the accuracy of the devices and posed potential health risks to customers [6]. - The company allegedly prioritized cost-cutting over safety, ignoring critical safety issues [6]. Stock Performance and Impact - DexCom's stock experienced significant declines due to revelations about quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [7]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [8]. - A report published on September 18, 2025, led to a nearly 12% decline, with the stock dropping $8.99 per share over two trading days [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the upcoming lead plaintiff deadline on December 29, 2025, for a class action lawsuit related to misleading statements made by the company [1]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to serve as lead plaintiff is December 29, 2025, which requires a motion to the Court [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company downplayed the severity of issues related to the G7 devices, leading to increased regulatory scrutiny and potential legal and financial repercussions [5]. - The lawsuit asserts that the public statements made by DexCom were materially false and misleading, resulting in investor damages when the true information became public [5].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud due to significant stock drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [4]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and posing health risks to customers [5]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to revelations about product quality issues, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [6]. - After the FDA published details of unauthorized modifications on March 25, 2025, the stock fell another $3.19 per share (over 4%) [7]. - A report by Hunterbrook on September 18 revealed severe issues, leading to a nearly 12% drop of $8.99 per share over two trading days [8].

Accessibility StatementSkip Navigation NEW YORK, Nov. 7, 2025 /PRNewswire/ --Â Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom, Inc." or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom, Inc. investors who were adversely affected by alleged securities fraud between July 26, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team: https://z ...

Core Insights - The Québec government has decided to expand coverage for Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible individuals aged 18 and older with type 2 diabetes on intensive insulin therapy [1] Group 1: Company Overview - Dexcom, Inc. is recognized as a global leader in glucose biosensing technology [1] - The expansion of coverage is expected to enhance access to CGM systems for a significant number of patients in Québec [1] Group 2: Industry Context - Type 2 diabetes is the most prevalent form of diabetes, affecting nearly 90% of individuals with the condition according to Diabète Québec [1] - The decision by the Québec government reflects a growing recognition of the importance of continuous glucose monitoring in managing diabetes effectively [1]

New York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...